Are described an amorphous solid dispersion comprising a 1:1 stoichiometric mixture of the sodium salts of Valsartan and Sacubitril useful in the treatment of essential hypertension and/or cardiac failure, possibly in the form of a pharmaceutical composition comprising said amorphous solid dispersion and at least one pharmaceutically acceptable carrier, as well as methods for the preparation of the amorphous solid dispersion.
